Status: Recruiting
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
Participants needed: 71
Trial details
Phase: Phase 2, Phase 3Age: 2-17Biological sex: AllType: InterventionalSponsor: Urovant Sciences GmbHUpdated: Jun 15, 2026Locations: 38
Eligibility criteria
Male or female participants, age 2 years to < 18 years and weighing at least 11... [+2]
Participant has cerebral palsy, uncontrolled epilepsy, diabetes insipidus, or St... [+17]